ScinoPharm Taiwan Ltd (台灣神隆), which makes made-to-order active pharmaceutical ingredients (API), yesterday completed the second stage of construction on its factory in Changshu in China’s Jiangsu Province.
The plant is set to boost the company’s total reactor volume by between 2.04 and 2.69 times to between 341,960 and 371,630 liters on both sides of the Taiwan Strait.
ScinoPharm’s pharmaceutical plant in Greater Tainan has a reactor volume of between 14,580 and 44,250 liters.
The second stage of construction included the building of a research and development center, as well as a multipurpose API plant, which can supply a larger variety of ingredients thanks to its two large production lines, the company said.
ScinoPharm has invested US$50 million to US$60 million in the two-stage project on a 40 hectare plot of land in the Chinese city, company president and chief executive Jo Shen (馬海怡) said yesterday.
The company plans to invest the same amount to build a formulation factory and expand its API production capacity on a nearby plot of land of a smiliar size, Shen said.
ScinoPharm has not made a timetable for its future investment because the schedule will depend on whether it can find Chinese partners to produce formulations, she said.
The Changshu factory has received drug production licenses from China’s Food and Drug Administration to manufacture four API products, but ScinoPharm still needs to apply for China’s good manufacturing practices certificates and drug permits for the four products before it can sell them on the market, she added.
ScinoPharm general manager Cheng Kuo-hsi (鄭國喜) said the factory is the first pharmaceutical plant in China that has complied with the country’s new good manufacturing standards.
The factory is expected to receive two drug permits in 2015 and 2016, after ScinoPharm and one of its clients submit the applications next year, Cheng said.
The Chinese facility began supplying intermediates to the company’s Greater Tainan factory in the second half of last year and is making drugs on a contract basis for two US companies and one Chinese firm, he added.
Meanwhile, the pharmaceutical ingredient maker is working with Chinese partners to sell its products across the Taiwan Strait and is in talks with another company in China to make drugs to treat glaucoma, according to Shen.
In Taiwan, ScinoPharm is building new production lines at its formulation factory in Greater Tainan, which may begin operating in the third quarter of next year, she said.
Alex Lo (羅智先), chairman of Uni-President Enterprise Co (統一企業), one of ScinoPharm’s largest shareholders, attended at the factory’s opening ceremony yesterday.
Companies affiliated with Uni-President own more than 60 percent of ScinoPharm shares.
Lo said Uni-President plans to follow in the footsteps of ScinoPharm and join its investment project.
“Uni-President will need the expertise of ScinoPharm to codevelop health products for the elderly,” he said.
From January through last month, ScinoPharm Taiwan registered revenue of NT$4.44 billion, up 9.87 percent from the NT$4.04 billion it made a year ago, while its net profit for the first three quarters was NT$1 billion, or NT$1.49 per share, up from NT$748.37 million, or NT$1.11 per share, the previous year.
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
RECORD-BREAKING: TSMC’s net profit last quarter beat market expectations by expanding 8.9% and it was the best first-quarter profit in the chipmaker’s history Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), which counts Nvidia Corp as a key customer, yesterday said that artificial intelligence (AI) server chip revenue is set to more than double this year from last year amid rising demand. The chipmaker expects the growth momentum to continue in the next five years with an annual compound growth rate of 50 percent, TSMC chief executive officer C.C. Wei (魏哲家) told investors yesterday. By 2028, AI chips’ contribution to revenue would climb to about 20 percent from a percentage in the low teens, Wei said. “Almost all the AI innovators are working with TSMC to address the
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”